Evidence map›Paper›PMID 42126937›Full record

ArticleCurrent protocols2026

Engineering, Expression, Purification, and Application of Glycosaminoglycan-Specific Antibodies.

Kheerthana Duraivelan, Sriram Sundaravel, Esther N Njoroge, Robert A Townley, Ulrich G Steidl, Hannes E Bülow, Steven C Almo, Scott J Garforth

Abstract read
In one paragraph

Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kheerthana DuraivelanDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Sriram SundaravelDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.
Esther N NjorogeDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Robert A TownleyDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Ulrich G SteidlDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.
Hannes E BülowMontefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York.
Steven C AlmoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Scott J GarforthDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
A Fluorescence-Based High-Throughput Platform for Glycotyping the Hematopoietic Cell LineageU01CA241981 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BUELOW, HANNES ERICH, STEIDL, ULRICH · 2019 to 2021
$1.3M
NCI NIH HHS P30CA013330NCI NIH HHS U01CA241981
6 · The paper itself

Abstract

Cluster of differentiation markers have been transformative for defining cell populations and their functional states, but recent work indicates that finer granularity can be achieved by considering the diverse heparan sulfate structures presented on proteoglycans. Heparan sulfates (HSs) are long, unbranched polysaccharides of a repeating disaccharide composed of hexuronic acid and N-acetylglucosamine. HS is attached to core proteins via serine residues. Owing to multiple modifications of the sugar moieties by a set of specific Golgi-resident modification enzymes, HSs exhibit extraordinary variations in modification patterns. Because these patterns are non-template based, they display substantial heterogeneity, yet are expressed reproducibly with high spatiotemporal and tissue-specific selectivity. This complexity of HS modification is, in turn, believed to control extracellular receptor:ligand interactions in a cell-specific fashion. Conventional methods to study HS structure require specialized expertise and instrumentation, and remain challenging due to the considerable heterogeneity of even tissue-specific HSs. Here, we describe protocols for the production and implementation of a panel of anti-HS single-chain variable fragments (scFvs) based on scFvs originally reported in the 1990s and early 2000s. This panel is an attractive resource for detailed study of HS modification patterns in various physiological processes. Rather than determining HS structure by analytical means, we use this panel to define cells based on the scFvs they bind. We detail practical considerations, strategies, and protocols for the construction, development, expression, purification, and application of the anti-HS scFv panel from bacterial and mammalian expression systems. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Expression and purification of anti-HS scFvs from bacterial expression systems Basic protocol 2: Expression and purification of anti-HS scFvs from mammalian expression systems Basic Protocol 3: Sortase-mediated site-specific labeling of anti-HS scFvs Basic Protocol 4: In vitro HS detection by ELISA Basic Protocol 5: In vitro HS detection by flow cytometry using indirect labeling in live Jurkat E6-1 cells Alternate Protocol 1: In vitro HS detection by flow cytometry using indirect labeling in fixed Vero cells Alternate Protocol 2: In vitro HS detection by flow cytometry using direct labeling in live Vero cells Basic Protocol 6: In vitro HS detection by immunofluorescence in fixed adherent cells Alternate Protocol 3: In vitro HS detection by immunofluorescence in suspension cells prior to fixation.

Indexed as

GlycosaminoglycansSingle-Chain AntibodiesAnimalsHeparan SulfateHumansGlycosaminoglycansHeparan SulfateSingle-Chain Antibodiesglycosaminoglycanheparan sulfateheterologous protein expression and purificationscFvsingle chain variable fragment

Identifiers

PMID42126937
PMCPMC13170773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.